Noritsugu Wada1, Katsuhito Mori2, Chie Nakagawa1, Jun Sawa1, Yasuro Kumeda1, Tetsuo Shoji3, Masanori Emoto4, Masaaki Inaba4. 1. Department of Internal Medicine, Minami-Osaka Hospital, Osaka, Japan. 2. Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. Electronic address: ktmori@med.osaka-cu.ac.jp. 3. Department of Geriatrics and Vascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. 4. Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Abstract
AIMS: Recent reports suggest that appropriate glycemic control without hypoglycemia could decrease mortality in patients with diabetes mellitus (DM) and end-stage renal disease (ESRD). However, an indication of oral anti-diabetic drugs is limited in this population. The aim of this study was to evaluate efficacy of teneligliptin, a novel DPP-4 inhibitor, by continuous glucose monitoring (CGM) in patients with type 2 DM (T2DM) on hemodialysis (HD). METHODS: This 4-week, open label, single arm, intervention trial included 10 diabetic patients undergoing HD and with glycated albumin (GA) level of ≥18.3%. Teneligliptin treatment was administered on days with HD sessions (HD day) and on days without HD sessions (NHD day); blood glucose values were measured by CGM. The primary endpoint was improvement of glycemic control evaluated by area under the curve (AUC). As secondary endpoints, changes in GA, HbA1c and fasting plasma glucose (FPG) were evaluated. RESULTS: Teneligliptin improved blood glucose AUC on both HD days (p=0.004), and NHD days (p=0.004). This was accompanied by a significant reduction in GA, HbA1c, and FPG, without severe hypoglycemia. CONCLUSIONS: Teneligliptin is one of the useful options for glycemic control in T2DM patients undergoing HD.
AIMS: Recent reports suggest that appropriate glycemic control without hypoglycemia could decrease mortality in patients with diabetes mellitus (DM) and end-stage renal disease (ESRD). However, an indication of oral anti-diabetic drugs is limited in this population. The aim of this study was to evaluate efficacy of teneligliptin, a novel DPP-4 inhibitor, by continuous glucose monitoring (CGM) in patients with type 2 DM (T2DM) on hemodialysis (HD). METHODS: This 4-week, open label, single arm, intervention trial included 10 diabeticpatients undergoing HD and with glycated albumin (GA) level of ≥18.3%. Teneligliptin treatment was administered on days with HD sessions (HD day) and on days without HD sessions (NHD day); blood glucose values were measured by CGM. The primary endpoint was improvement of glycemic control evaluated by area under the curve (AUC). As secondary endpoints, changes in GA, HbA1c and fasting plasma glucose (FPG) were evaluated. RESULTS:Teneligliptin improved blood glucose AUC on both HD days (p=0.004), and NHD days (p=0.004). This was accompanied by a significant reduction in GA, HbA1c, and FPG, without severe hypoglycemia. CONCLUSIONS:Teneligliptin is one of the useful options for glycemic control in T2DM patients undergoing HD.
Authors: Oliver Schnell; Katharine Barnard; Richard Bergenstal; Emanuele Bosi; Satish Garg; Bruno Guerci; Thomas Haak; Irl B Hirsch; Linong Ji; Shashank R Joshi; Maarten Kamp; Lori Laffel; Chantal Mathieu; William H Polonsky; Frank Snoek; Philip Home Journal: Diabetes Technol Ther Date: 2017-05-22 Impact factor: 6.118
Authors: K Mori; M Emoto; R Numaguchi; Y Yamazaki; H Urata; K Motoyama; T Morioka; T Shoji; M Inaba Journal: Acta Endocrinol (Buchar) Date: 2017 Apr-Jun Impact factor: 0.877